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Introduction 
Fibrosis is characterized by extracellular matrix (ECM) remodeling and stiffening. However, functional 
contribution of tissue stiffening to non-cancer pathogenesis remains largely unknown. Fibronectin is an ECM 
glycoprotein substantially expressed during tissue repair. We have previously demonstrated using a mouse 
model lacking fibronectin that fibronectin-null livers do not interfere with reconstruction and resolution of 
collagen organization in initial stages of liver damage (Gastroenterology, 2011). However, it remains unknown 
whether the extent of the initial fibronectin deposition could contribute to the critical turning point from normal 
to abnormal healing during the development of chronic tissue fibrosis. Furthermore, how remodeling of ECM 
by myofibroblasts results in changes in mechanical tension that support the activation of pathogenic signaling 
pathways remain to be elucidated. 
 
Materials and Methods 
We utilized fibronectin-floxed mice and generated adult “liver fibronectin-null (mutant)” mice 
(fibronectin(fl/fl)/Mx-Cre+). Chronic liver injury was induced by well-established treatments with carbon 
tetrachloride.   
 
Results 
Unexpectedly, fibronectin-null livers lead to more extensive liver cirrhosis, which is accompanied by increased 
liver matrix stiffness and deteriorated hepatic functions. Furthermore, fibronectin-null livers exhibit more 
myofibroblast phenotypes, and accumulate highly disorganized/diffuse collagenous ECM composed of 
thinner and significantly increased number of collagen fibrils during advanced chronic liver damage. 
Mechanistically, mutant livers show elevated local TGF-β activity and lysyl oxidase expressions. A significant 
amount of active lysyl oxidase is released in fibronectin-null hepatic stellate cells in response to TGF-β1 
through canonical and non-canonical Smad such as PI3 kinase-mediated pathways. TGF-β1-induced 
collagen fibril stiffness in fibronectin-null hepatic stellate cells is significantly higher compared to wild-type 
cells. Inhibition of lysyl oxidase significantly reduces collagen fibril stiffness, and treatment of fibronectin 
recovers collagen fibril stiffness to wild-type levels. 
 
Discussion 
Thus, our findings indicate an indispensable role for fibronectin in chronic liver fibrosis/cirrshosis in negatively 
regulating TGF-β bioavailability, which in turn modulates ECM remodeling and stiffening, and consequently 
preserves adult organ functions. This regulatory mechanism by fibronectin could be translated for a potential 
therapeutic target in broader variety of chronic fibrotic diseases. 
 
Reference 
Moriya K, Bae E, Honda K, Sakai K, Sakaguchi T, Tsujimoto I, Kamisoyama H, Keene DR, Sasaki T, Sakai 
T. (2011) A fibronectin-independent mechanism of collagen fibrillogenesis in adult liver remodeling. 
Gastroenterology 140:1653-1663.  
